
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 24 years ago
Study Documents How Price of TNF Inhibitors Rose After New Competitionalmost 24 years ago
Considerations for Implementing a New Combination Vaccine into Managed Carealmost 24 years ago
The Future of Childhood Immunizations: Examining the European Experiencealmost 24 years ago
Participating Faculty





